Stockreport

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 [Yahoo! Finance]

Lyell Immunopharma, Inc.  (LYEL) 
PDF LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR) T-cell product candidate enhanced with proprietary anti-exhaustion technology; 40% objective response rate and 60 [Read more]